Understanding kidney problems caused by cancer immunotherapy
Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer
This study is looking at how certain cancer treatments can sometimes harm the kidneys, and it's for patients who have had kidney problems after these treatments; by examining samples from these patients, researchers hope to understand why this happens and find ways to prevent or fix these issues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11092222 on NIH RePORTER |
What this research studies
This research investigates how immune checkpoint inhibitors, which are used to treat cancer, can lead to kidney injuries in some patients. By enrolling patients who have experienced kidney issues after receiving these therapies, the study will analyze kidney tissue, blood, and urine samples using advanced techniques like single-cell RNA sequencing. The goal is to uncover the underlying mechanisms of kidney damage, which could help in developing strategies to prevent or treat these complications in the future.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who have developed acute interstitial nephritis or other kidney issues after receiving immune checkpoint inhibitors.
Not a fit: Patients who have not received immune checkpoint inhibitors or those without kidney complications from cancer treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better management and prevention of kidney injuries in cancer patients undergoing immunotherapy.
How similar studies have performed: While there has been descriptive research on immune-related adverse events, this study aims to provide novel insights into the specific mechanisms of kidney injury, making it a potentially groundbreaking approach.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Sise, Meghan E. — Massachusetts General Hospital
- Study coordinator: Sise, Meghan E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.